2025 stands as a milestone-rich year for CRISPR Therapeutics. In addition to the continued launch progress of CASGEVY, we expect several key milestones across our pipeline, including updates on ...

CRISPR Therapeutics stands at a pivotal moment in its journey as a pioneering gene editing company. With Casgevy's launch underway and a rich pipeline of potential therapies, the company has the ...

CRISPR Therapeutics AG (CRSP) stock jumped over 9% this week after delivering strong Q4 2024 results ahead of schedule. The headline numbers were ahead of estimates, while the pipeline details ...

That is not just the case for Casgevy, but across many of Crispr Therapeutics' other pipeline projects, which we'll now take a closer look at. Crispr Therapeutics has been working with cell ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the ...

BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP ... cash to support “years of development in the pipeline,” the firm remains positive on the Crispr ...

With its flagship product Casgevy gaining traction and a diverse pipeline spanning multiple therapeutic areas, the company faces both significant opportunities and challenges in the rapidly evolving ...

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But ...

CRISPR Therapeutics CRSP stock rose more than 25 ... Alongside earnings results, management also cited pipeline advancements and updates on nearly all its pipeline candidates expected throughout ...

CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...